Invest in the Future of Eliaz Therapeutics

Explore our active investment opportunities.

View our Reg D Offering

This Reg CF offering is made available through StartEngine Primary, LLC, member FINRA/SIPC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. In addition to our Reg CF offering, Eliaz Therapeutics may conduct private offerings pursuant to Regulation D (Rule 506(c), available only to accredited investors).

Our our Reg CF equity round is officially closed on StartEngine!

Thank you to all of our investors who recently participated in our Regulation Crowdfunding campaign with StartEngine. This campaign closed on April 30th, 2026.

View Our Equity Round on StartEngine

For Accredited Investors:
Regulation D Offering

For Accredited Investors:
Regulation D Offering

For Accredited Investors:
Regulation D Offering

This offering is conducted pursuant to Regulation D, Rule 506(c), and is available exclusively to accredited investors. Verification is required prior to participation. Investments are speculative, illiquid, and involve a high degree of risk, including possible loss of principal.

This offering is conducted pursuant to Regulation D, Rule 506(c), and is available exclusively to accredited investors. Verification is required prior to participation. Investments are speculative, illiquid, and involve a high degree of risk, including possible loss of principal.

Investor Highlights

$1.9M raised from NIH Grant

$3.4M+ raised via Crowdfunding

For more information regarding investor relations, please contact us below.

Modern office interior with glass walls, wooden accents, and a person walking up a staircase in motion blur.

Investor Relations

Address

398 Tesconi Ct.
Santa Rosa, CA
95401

Email

info@eliaztherapeutics.com

398 Tesconi Ct
Santa Rosa, CA 95401
United States

Email

info@eliaztherapeutics.com

Technology

Problem/Solution

XGal-3® Device

Company

Team

Press Room

Investor Relations

2026 Form C-AR

Research

Publications

Intellectual Property

FCOI

The content on this website is for general informational purposes only and does not constitute medical advice, diagnosis, or treatment. Our product(s) are in development, not approved for commercial use, and not available for sale. Any forward-looking statements reflect current plans and expectations, which may change. If you choose to visit our crowdfunding campaign, please be aware that investing involves risk and should not be considered a guarantee of future outcomes. Mention of third-party organizations does not imply affiliation unless explicitly stated. All trademarks, logos, and technologies referenced are the property of Eliaz Therapeutics or its licensors and may not be used without written permission. In addition to our Reg CF offering, Eliaz Therapeutics may conduct private offerings pursuant to Regulation D (Rule 506(c), available only to accredited investors).

NO MONEY OR OTHER CONSIDERATION IS BEING SOLICITED, AND IF SENT IN RESPONSE, WILL NOT BE ACCEPTED. NO OFFER TO BUY THE SECURITIES CAN BE ACCEPTED AND NO PART OF THE PURCHASE PRICE CAN BE RECEIVED UNTIL THE OFFERING STATEMENT HAS BEEN QUALIFIED BY THE SEC. ANY SUCH OFFER MAY BE WITHDRAWN OR REVOKED, WITHOUT OBLIGATION OR COMMITMENT OF ANY KIND, AT ANY TIME BEFORE NOTICE OF ACCEPTANCE GIVEN AFTER THE DATE OF QUALIFICATION. AN INDICATION OF INTEREST INVOLVES NO OBLIGATION OR COMMITMENT OF ANY KIND. "RESERVING" SECURITIES IS SIMPLY AN INDICATION OF INTEREST.

398 Tesconi Ct
Santa Rosa, CA 95401
United States

Email

info@eliaztherapeutics.com

Technology

Problem/Solution

XGal-3® Device

Company

Team

Press Room

Investor Relations

2026 Form C-AR

Research

Publications

Intellectual Property

FCOI

The content on this website is for general informational purposes only and does not constitute medical advice, diagnosis, or treatment. Our product(s) are in development, not approved for commercial use, and not available for sale. Any forward-looking statements reflect current plans and expectations, which may change. If you choose to visit our crowdfunding campaign, please be aware that investing involves risk and should not be considered a guarantee of future outcomes. Mention of third-party organizations does not imply affiliation unless explicitly stated. All trademarks, logos, and technologies referenced are the property of Eliaz Therapeutics or its licensors and may not be used without written permission. In addition to our Reg CF offering, Eliaz Therapeutics may conduct private offerings pursuant to Regulation D (Rule 506(c), available only to accredited investors).

NO MONEY OR OTHER CONSIDERATION IS BEING SOLICITED, AND IF SENT IN RESPONSE, WILL NOT BE ACCEPTED. NO OFFER TO BUY THE SECURITIES CAN BE ACCEPTED AND NO PART OF THE PURCHASE PRICE CAN BE RECEIVED UNTIL THE OFFERING STATEMENT HAS BEEN QUALIFIED BY THE SEC. ANY SUCH OFFER MAY BE WITHDRAWN OR REVOKED, WITHOUT OBLIGATION OR COMMITMENT OF ANY KIND, AT ANY TIME BEFORE NOTICE OF ACCEPTANCE GIVEN AFTER THE DATE OF QUALIFICATION. AN INDICATION OF INTEREST INVOLVES NO OBLIGATION OR COMMITMENT OF ANY KIND. "RESERVING" SECURITIES IS SIMPLY AN INDICATION OF INTEREST.

398 Tesconi Ct
Santa Rosa, CA 95401
United States

Email

info@eliaztherapeutics.com

Technology

Problem/Solution

XGal-3® Device

Company

Team

Press Room

Investor Relations

2026 Form C-AR

Research

Publications

Intellectual Property

FCOI

The content on this website is for general informational purposes only and does not constitute medical advice, diagnosis, or treatment. Our product(s) are in development, not approved for commercial use, and not available for sale. Any forward-looking statements reflect current plans and expectations, which may change. If you choose to visit our crowdfunding campaign, please be aware that investing involves risk and should not be considered a guarantee of future outcomes. Mention of third-party organizations does not imply affiliation unless explicitly stated. All trademarks, logos, and technologies referenced are the property of Eliaz Therapeutics or its licensors and may not be used without written permission. In addition to our Reg CF offering, Eliaz Therapeutics may conduct private offerings pursuant to Regulation D (Rule 506(c), available only to accredited investors).

NO MONEY OR OTHER CONSIDERATION IS BEING SOLICITED, AND IF SENT IN RESPONSE, WILL NOT BE ACCEPTED. NO OFFER TO BUY THE SECURITIES CAN BE ACCEPTED AND NO PART OF THE PURCHASE PRICE CAN BE RECEIVED UNTIL THE OFFERING STATEMENT HAS BEEN QUALIFIED BY THE SEC. ANY SUCH OFFER MAY BE WITHDRAWN OR REVOKED, WITHOUT OBLIGATION OR COMMITMENT OF ANY KIND, AT ANY TIME BEFORE NOTICE OF ACCEPTANCE GIVEN AFTER THE DATE OF QUALIFICATION. AN INDICATION OF INTEREST INVOLVES NO OBLIGATION OR COMMITMENT OF ANY KIND. "RESERVING" SECURITIES IS SIMPLY AN INDICATION OF INTEREST.